Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31020826 | 1.00 | CHRNA7 (0.68) | CHRNA7LMNAMAPTHPGDKDM4E | |
| SCHEMBL23928866 | 0.91 | CHRNA7 (0.82) | CHRNA7LMNAMAPTHPGDKDM4E | |
| SCHEMBL31020806 | 0.91 | CHRNA7 (0.82) | CHRNA7LMNAMAPTHPGDKDM4E | |
| SCHEMBL23928862 | 0.84 | CHRNA7 (0.82) | CHRNA7LMNAMAPTHPGDKDM4E | |
| SCHEMBL23957173 | 0.82 | CHRNA7 (0.82) | CHRNA7LMNAHPGDKDM4EALDH1A1 | |
| SCHEMBL31020812 | 0.81 | CHRNA7 (1.00) | CHRNA7LMNAMAPTHPGDKDM4E | |
| SCHEMBL23928854 | 0.81 | CHRNA7 (1.00) | CHRNA7LMNAMAPTHPGDKDM4E | |
| SCHEMBL21617953 | 0.80 | CHRNA7 (1.00) | CHRNA7LMNAMAPTHPGDKDM4E | |
| SCHEMBL31020824 | 0.80 | CHRNA7 (1.00) | CHRNA7LMNAMAPTHPGDKDM4E | |
| SCHEMBL23928857 | 0.80 | CHRNA7 (0.82) | CHRNA7LMNAMAPTHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820869-B1 | SPIROCHROMANE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2023-08-30 | — | — | EP | disclosed |
| US-20210330650-A1 | SPIROCHROMANE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2021-10-28 | — | — | US | disclosed |
| US-20210330650-A1 | SPIROCHROMANE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2021-10-28 | — | — | US | disclosed |
| CN-112823157-A | Spirochroman derivatives | 吉瑞工厂 | 2021-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330650-A1 | SPIROCHROMANE DERIVATIVES | CHRNA7, CHRM3, ADRB3 | CHRNA7 1/4885LMNA 517/4885MAPT 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.